Who owns SYRE?
Institutional ownership of Spyre Therapeutics Inc. from Form 13F, Q2 2026
265 institutional managers reported holding Spyre Therapeutics Inc. (SYRE) in Form 13F filings for Q2 2026, with 95,817,421 shares worth $8.5B. The largest reported holder was FMR LLC. Managers that filed both quarters added a net 12,438,262 shares (+15.3%). 88 opened new positions and 21 sold out.
- Funds holding
- 265
- Value held
- $8.5B
- New / sold out
- 88 / 21
- Net shares, same filers
- +15.3%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of SYRE
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| FMR LLC | $1.2B | 13.6% | 13,026,187 | Added |
| BlackRock, Inc. | $578M | 6.8% | 6,506,605 | Added |
| Perceptive Advisors LLC | $383M | 4.5% | 4,319,496 | Added |
| RTW Investments, LP | $377M | 4.4% | 4,251,996 | Added |
| Paradigm Biocapital Advisors LP | $341M | 4.0% | 3,840,778 | Added |
| Vanguard Capital Management LLC | $306M | 3.6% | 3,448,681 | Added |
| State Street Corp | $271M | 3.2% | 3,057,416 | Added |
| Venrock Adviser, LLC | $265M | 3.1% | 2,985,448 | Trimmed |
| Price T Rowe Associates Inc | $263M | 3.1% | 2,960,855 | Added |
| Driehaus Capital Management LLC | $249M | 2.9% | 2,799,166 | Added |
| Geode Capital Management, LLC | $239M | 2.7% | 2,562,265 | Added |
| Vanguard Portfolio Management LLC | $207M | 2.4% | 2,330,098 | Added |
| Capital World Investors | $206M | 2.4% | 2,315,553 | Added |
| Jupiter Topco LLC | $196M | 2.3% | 2,206,936 | First report |
| TCG Crossover Management, LLC | $169M | 2.0% | 1,900,582 | Unchanged |
| Tang Capital Management LLC | $168M | 2.0% | 1,892,200 | Unchanged |
| Bank of America Corp | $158M | 1.9% | 1,777,854 | Added |
| Adage Capital Partners GP, L.l.c. | $153M | 1.8% | 1,722,300 | New |
| Wellington Management Group LLP | $140M | 1.7% | 1,581,505 | Trimmed |
| Goldman Sachs Group Inc | $131M | 1.5% | 1,478,059 | Added |
| Franklin Resources Inc | $131M | 1.5% | 1,472,943 | Added |
| Remedium Capital Partners, LLC | $130M | 1.5% | 1,464,169 | Added |
| Affinity Asset Advisors, LLC | $114M | 1.3% | 1,279,134 | Unchanged |
| JPMorgan Chase & Co | $98.9M | 1.1% | 1,093,026 | Added |
| Holocene Advisors, LP | $90.1M | 1.1% | 1,015,170 | New |
Share of 13F holdings is each fund's shares as a share of the 95,817,421 SYRE shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Paradigm Biocapital Advisors LP Added+$167M
- Vanguard Portfolio Management LLC Added+$155M
- Adage Capital Partners GP, L.l.c. New+$153M
- Capital World Investors Added+$146M
- Price T Rowe Associates Inc Added+$121M
- FMR LLC Added+$111M
- Goldman Sachs Group Inc Added+$107M
- Holocene Advisors, LP New+$90.1M
- BlackRock, Inc. Added+$87.5M
- Geode Capital Management, LLC Added+$78.6M
Biggest sellers in Q2 2026
- Fairmount Funds Management LLC Sold out-$203M
- Commodore Capital LP Trimmed-$94.6M
- Ra Capital Management, L.p. Sold out-$81.8M
- Capital International Investors Trimmed-$70.2M
- Venrock Adviser, LLC Trimmed-$62.1M
- Baker Bros. Advisors LP Sold out-$50.4M
- Caligan Partners LP Sold out-$44.3M
- Wellington Management Group LLP Trimmed-$21.6M
- Stempoint Capital LP Trimmed-$20.3M
- Boothbay Fund Management, LLC Trimmed-$16.6M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $2.2B and sold $768M; 102 added and 55 trimmed.
Schedule 13D and 13G filings on SYRE
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-04-22PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by Spyre Therapeutics Inc.Schedule 13G
- 2025-07-29VANGUARD GROUP INC SCHEDULE 13G filed by Spyre Therapeutics Inc.Schedule 13G
- 2025-05-01TANG CAPITAL MANAGEMENT LLC SCHEDULE 13G filed by Spyre Therapeutics Inc.Schedule 13G
Questions about SYRE ownership
- Who owns SYRE stock?
- 265 institutional investment managers reported SYRE positions in their Form 13F filings for Q2 2026, holding 95,817,421 shares worth $8.5B in total. FMR LLC reported the largest position.
- Are funds buying or selling SYRE?
- In Q2 2026, 88 managers opened new SYRE positions, 102 added, 55 trimmed and 21 sold out. Managers that filed in both quarters added a net 12,438,262 shares.
- How current is this SYRE institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to SYRE by CUSIP. Options are left out. SYRE news and filings · SYRE insider trades · Top funds